Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The proteasome 20S subunit beta type refers to the β subunits (β1 through β7) of the 20S core proteasome, a barrel-shaped complex of four heptameric rings (α7-β7-β7-α7) responsible for degrading ubiquitinated proteins into peptides via threonine protease activity. The catalytic β subunits (β1, β2, β5) feature N-terminal propeptides that are autocatalytically cleaved during maturation, exposing the active Thr1 residue; β1 exhibits caspase-like (post-acidic) activity, β2 trypsin-like (basic residues), and β5 chymotrypsin-like (hydrophobic residues). These subunits assemble stepwise with chaperones like PAC1-4 and POMP, enabling protein homeostasis, cell cycle regulation, and antigen processing. Note: "Proteasome 20S subunit beta type" is nonspecific (generic class, not a single isoform like PSMB5); specify isoform (e.g., "Proteasome 20S subunit beta 5") for precise targeting. Drugs primarily target catalytic sites in β1/β2/β5 for cancer therapy.
Inhibition of chymotrypsin-like activity (β5), inhibition of trypsin-like activity (β2), inhibition of caspase-like activity (β1), and covalent binding to N-terminal threonine.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome 20S subunit beta type.